English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/165573
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Levothyroxine enhances glucose clearance and blunts the onset of experimental type 1 diabetes mellitus in mice

AuthorsLópez-Noriega, Livia; Cobo-Vuilleumier, Nadia ; Narbona-Pérez, Álvaro Jesús; Araujo-Garrido, Juan Luis; Lorenzo, Petra Isabel ; Mellado-Gil, José Manuel ; Moreno, José Carlos; Gauthier, Benoit R.; Martín-Montalvo, Alejandro
Issue Date2017
PublisherJohn Wiley & Sons
British Pharmacological Society
CitationBritish Journal of Pharmacology 174(21): 3795-3810 (2017)
Abstract[Background and Purpose]: Thyroid hormones induce several changes in whole body metabolism that are known to improve metabolic homeostasis. However, adverse side effects have prevented its use in the clinic. In view of the promising effects of thyroid hormones, we investigated the effects of levothyroxine supplementation on glucose homeostasis. [Experimental Approach]: C57BL/6 mice were treated with levothyroxine from birth to 24 weeks of age, when mice were killed. The effects of levothyroxine supplementation on metabolic health were determined. C57BL/6 mice treated with levothyroxine for 2 weeks and then challenged with streptozotocin to monitor survival. Mechanistic experiments were conducted in the pancreas, liver and skeletal muscle. RIP-B7.1 mice were treated with levothyroxine for 2 weeks and were subsequently immunized to trigger experimental autoimmune diabetes (EAD). Metabolic tests were performed. Mice were killed and metabolic tissues were extracted for immunohistological analyses. [Key Results]: Long-term levothyroxine supplementation enhanced glucose clearance and reduced circulating glucose in C57BL/6 mice. Levothyroxine increased simultaneously the proliferation and apoptosis of pancreatic beta cells, promoting the maintenance of a highly insulin-expressing beta cell population. Levothyroxine increased circulating insulin levels, inducing sustained activation of IRS1-AKT signalling in insulin-target tissues. Levothyroxine-treated C57BL/6 mice challenged with streptozotocin exhibited extended survival. Levothyroxine blunted the onset of EAD in RIP-B7.1 mice by inducing beta cell proliferation and preservation of insulin-expressing cells. [Conclusions and Implications]: Interventions based on the use of thyroid hormones or thyromimetics could be explored to provide therapeutic benefit in patients with type 1 diabetes mellitus.
URIhttp://hdl.handle.net/10261/165573
Identifiersdoi: 10.1111/bph.13975
e-issn: 1476-5381
issn: 0007-1188
Appears in Collections:(CABIMER) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.